Anna Shadman is a senior biopharmaceutical executive with more than three decades of progressive leadership experience across small, mid-sized, and global pharmaceutical companies. She has a proven track record of advancing through increasingly senior roles and consistently delivering both strategic and operational impact.
An accomplished leader in end-to-end drug development, Anna has deep expertise in guiding programs from New Molecular Entity (NME) declaration through commercialization. Her broad experience across multiple functions in the drug development ecosystem—combined with strong leadership and stakeholder management skills—enables her to forge highly effective strategic partnerships and deliver a clear program and portfolio vision. She is adept at integrating cross-functional considerations across Clinical Development, Regulatory Affairs, Manufacturing, Medical Affairs, Program Management, and other critical disciplines. Her core strengths include maximizing portfolio value—both organically and inorganically—while balancing trade-offs, shaping portfolio strategy, and aligning with corporate vision and growth ambitions.
Most recently, Anna served as Senior Vice President, Medicine Development Leaders, at GSK, and as Senior Vice President, Product Portfolio & Strategy, at Gilead—together spanning a five-year period. In these roles, she led teams of Program Leaders focused on advancing medicines to market and expanding therapeutic portfolios across Immunology & Inflammation, Oncology, Respiratory, HIV, Neuroscience, and Infectious Diseases. She played a central role in due diligence and business development, asset acquisitions, post-merger integration, and served on multiple Development and Investment Boards.
Previously, Anna held senior leadership positions at Amgen as Global Product General Manager and at Janssen Pharmaceuticals (Johnson & Johnson) as Compound Development Team Leader. She led the cross-functional team responsible for the development and launch of Aimovig® for migraine prevention, and at Janssen Alzheimer Immunotherapy, she advanced programs targeting treatments for Alzheimer’s disease while serving as a Board Director.
Earlier in her career, Anna held roles of increasing responsibility in Clinical Development Operations, Program Management, and Biostatistics, where she began her pharmaceutical career. She holds a BSc in Mathematics and an MSc in Medical Statistics.
Throughout her career, Anna has been driven by a passion for delivering transformative treatments to patients and by commitment to crafting integrated strategies that address the needs of regulators, healthcare systems, payers, and the broader ecosystem that supports new medicines. She is equally dedicated to developing talent, coaching and mentoring high-performing teams, and fostering strong collaboration across internal teams, senior executives, and external partners.